A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam
study id #: NCT05067790
condition: Spinal Muscular Atrophy
status: Not yet recruitingpurpose:
The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy (SMA) previously treated with risdiplam.
The secondary objective of this study is to evaluate the safety and tolerability of HD nusinersen in participants with SMA previously treated with risdiplam.
last updated: February 04, 2022
start date: November 22, 2021
estimated completion: June 14, 2027
last updated: October 5, 2021
phase of development: Phase 3
size / enrollment: 135
- Change in Total Revised Upper Limb Module (RULM) Score
The RULM is being utilized to assess upper limb functional abilities of participants with SMA. This test consists of upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.
- Up to Day 855
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Up to Day 855
- Number of Participants With Change from Baseline in Clinical Laboratory Parameters, Electrocardiogram (ECG), Vital Signs and Pulse Oximetry
Up to Day 855
• Eligible Sexes: all
Genetic documentation of 5q SMA homozygous survival motor neuron-1 (SMN1) gene deletion or mutation or compound heterozygous mutation.
Diagnosis of later-onset SMA with symptom onset at age >6 months.
Aged ≥5 to ≤39 years at the time of informed consent for nusinersen-naïve participants.
Aged ≥18 to ≤39 years at time of informed consent for nusinersen-experienced participants.
Body weight >20 kg.
Received oral risdiplam per the approved label or per the managed access program as follows Nusinersen-naive participants must have had prior treatment with risdiplam for ≥6 months and ≤12 months before enrollment.
Nusinersen-experienced participants must have stopped nusinersen for ≥16 months and have been on risdiplam for ≥12 months and ≤18 months before enrollment.
Able to perform the age-appropriate functional assessments in the study.
RULM entry item A score ≥3.
RULM total score ≥5 and ≤30 at Screening.
Nonambulatory, defined as not able to walk 15 feet (4.57 meters) independently without support.
Willing to stop risdiplam treatment.
Willing and able to start treatment with nusinersen.
exclusion criteria: Criteria:
Any major illness within 1 month before the Screening examination or within 1 week prior to Screening and up to first dose administration.
Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the Screening Period.
Presence of an implanted shunt for the drainage of CSF or of an implanted central nervous system catheter.
History of bacterial meningitis, viral encephalitis, or hydrocephalus.
Ongoing medical condition that according to the Investigator would interfere with the conduct and assessments of the study. An example is a medical disability (e.g., wasting or cachexia, severe anemia, and respiratory parameters) that would interfere with the assessment of safety or would compromise the ability of the participant to undergo study procedures.
Participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study.
Treatment with an investigational drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to Screening or anytime during the study; any prior or current treatment with gene therapy for the treatment of SMA.
NOTE: Other protocol defined Inclusion/
Matthew Harms, MDMatthew Harms, MD is an Associate Profes...
Spinal Muscular Atrophy 2019: Infantile Onset Spinal Muscular Atrophyhttps://www.youtube.com/watch?v=t6UO6bKO...
Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy—Protocol ...Spinal muscular atrophy (SMA) is a rare ...
Brian G. Smith, MD, FAAP, FAOADr. Smith became the Chief of the Divisi...
A Novel CARM1-HuR Axis Involved in Muscle Differentiation and Plasticity Misregulated in Spinal Muscular AtrophySpinal muscular atrophy (SMA) is charact...
Spinal Muscular Atrophy Type 2 (Intermediate SMA)Spinal muscular atrophy (SMA) is a genet...
How One Mother Is Raising Awareness for Spinal Muscular Atrophy – A Leading Genetic Cause of Infant DeathWhen Nicole Clark’s son Brady was born...